No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases Medical Xpress
Registration for the Fall 2019 Group Meeting will open by late August. Email announcements will circulate when registration opens.
The CRA Core Committee is offering limited travel assistance to the Fall 2019 Group Meeting More Here
Call for Abstracts: Young investigators interested in presenting your research at the Fall 2019 Group Meeting may submit an abstract now Apply Here
Don’t miss the June 2019 Newsletter
Like what you’re reading? We want your feedback! Please take a two-minute newsletter Readership Survey
ComboMATCH concept sheets are being accepted until further notice More Here
NEW! Did you know there is a new TMIST newsletter? More Here
The results of leukemia trial E1912 are published in The New England Journal of Medicine. Tait Shanafelt, MD (Stanford University) and colleagues report that treatment with the combination of ibrutinib and rituximab is superior to standard treatment for patients 70 years of age or younger, with chronic lymphocytic leukemia (CLL) More Here
The Journal of Clinical Oncology has published the results of the ACRIN 6685 trial. Val J. Lowe, MD (Mayo Clinic) and colleagues report that surgical planning for head and neck cancer benefits from FDG-PET/CT, especially in patients who are clinically node-negative More Here
San Antonio Breast Cancer Symposium honors ECOG-ACRIN vice chair Joseph A. Sparano, MD with its prestigious William L. McGuire Memorial Lecture Award More Here
Amy Curtis, MD (Spartanburg Medical Center): Women are intrigued by the many questions asked in TMIST Conversation with The Cancer Letter
Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.
The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.
We look forward to sharing our research and partnering with you, as we reshape the future of patient care.
Robert L. Comis, MD